Chengdu Baiyu enters into a license agreement for the development and commercialization of its Anti-tumor small molecule inhibitor
Chengdu Baiyu Pharmaceutical Co., Ltd. (Chengdu, China) announced that it has entered into an exclusive license agreement with Novartis for a small molecule anti-tumor asset.